<DOC>
	<DOCNO>NCT00060632</DOCNO>
	<brief_summary>Phase 1 trial determine safety , tolerability maximum tolerate dose ( MTD ) ridaforolimus patient refractory recurrent malignancy , include myeloma lymphoma .</brief_summary>
	<brief_title>Safety Study Ridaforolimus Patients With Advanced , Refractory Recurrent Malignancies ( MK-8669-001 AM5 ) ( COMPLETED )</brief_title>
	<detailed_description>The primary objective study determine safety , tolerability , MTD ridaforolimus administer weekly 4 week ( 4 week cycle ) . The secondary objective study characterize pharmacokinetic profile ridaforolimus , evaluate potential pharmacodynamic marker ridaforolimus , obtain preliminary information antineoplastic activity ridaforolimus . Protocol Outline : This dose-escalation study . Patients receive ridaforolimus 30 minute intravenous infusion weekly 8 week ( two 4-week cycle ) . If tolerate , total least 2 cycle administer ( 8-week treatment period ) . Treatment repeat every 4 week absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>( Patients must meet follow criterion eligible participation study ) . Male female patient , ≥ 18 year age . Patients document measurable evaluable malignancy , include myeloma lymphoma , recurrent , advance , metastatic . Patients disease currently refractory , amenable , standard therapy . Patients disease currently amenable surgical intervention . Patients Karnofsky performance status ≥ 70 % ( Eastern Cooperative Oncology Group [ ECOG ] performance status 0 1 ) anticipate life expectancy ≥ 3 month . Patients either childbearing potential , agree use medically effective method contraception . Patients ability understand give write informed consent . ( Patients meeting follow criterion ineligible participation study ) Women pregnant lactating . Patients primary central nervous system ( CNS ) malignancy . Patients leukemia , form . Patients certain hematologic abnormality . Patients certain serum chemistry abnormality baseline . Patients know suspected hypersensitivity either drug formulate polysorbate 80 ( Tween 80 ) excipient contain test drug formulation . Patients know hypersensitivity macrolide antibiotic ( e.g. , clarithromycin , erythromycin , azithromycin ) . Patients significant cardiovascular disease . Patients active CNS metastasis ( leptomeningeal disease ) control prior surgery radiotherapy . Note : Patients treat brain metastasis eligible stable dose corticosteroid without change brain disease status least 4 week follow related therapy ( e.g. , whole brain radiation , surgery ) . Patients know human immunodeficiency virus ( HIV ) infection . Patients active infection . Patients inadequate recovery prior surgical procedure , patient undergo major surgical procedure within 2 week prior study entry . Note : Patients undergone recent placement central venous access port consider eligible enrollment recover . Patients lifethreatening illness organ system dysfunction , opinion Investigator , would either compromise patient 's safety interfere evaluation safety test drug . Patients psychiatric disorder alter mental status would preclude understand informed consent process and/or completion necessary study . Patients inability , opinion Investigator , comply protocol requirement . Drugs Other Treatments Excluded ( Either within 4 week prior study entry , unless otherwise note ) Chemotherapeutic agent ( standard experimental ) . Other antineoplastic agent . Immunotherapy ( include vaccine ) biological response modifier therapy . Systemic replacement hormonal therapy lifethreatening nononcology disease . Herbal preparation related overthecounter ( OTC ) preparation contain herbal ingredient ( e.g. , St John 's Wort ) within 2 week prior study entry . Any prior therapy rapamycin , CCI779 , rapamycin analog . Any experimental therapy course study . Radiotherapy primary malignancy metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Advanced , refractory recurrent solid tumor</keyword>
</DOC>